CytomX Therapeutics, Inc. (CTMX) Stock

CytomX Therapeutics, Inc. (CTMX) is a Healthcare stock trading at $2.96 (as of 2026-06-18), with a market capitalization of $783.73M and a trailing P/E of -5.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CytomX Therapeutics, Inc. develops oncology therapeutics in the United States, including antibody-based drug candidates built on its Probody technology platform. Its pipeline includes multiple Probody therapeutics and conditionally activated antibody drug conjugates targeting cancer-associated proteins, which are being studied in clinical trials across several cancer types.

Valuation — source: SEC EDGAR (first-party)
Price$2.96
Market Cap$783.73M
P/E Ratio-5.8
EV / EBITDA-9.9
Price / Book2.05
Price / Sales18.44
DCF Value (model)$-7.51
DCF Upside vs Price-354.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$76.20M
Net Margin-22.8%
Return on Equity-18.5%
Current Ratio10.38
Revenue Growth (YoY)-44.8%
FCF Growth (YoY)-12.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.05 (distress)
Valuation vs Sector & Industry
Stock P/E-5.8
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-127.7%
vs Industry-134.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($150.19M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSean A. McCarthy
Employees119
CountryUS
IPO Date2015-10-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Jade Biosciences, Inc. (JBIO)
  • Arvinas, Inc. (ARVN)
  • Fulcrum Therapeutics, Inc. (FULC)
  • Replimune Group, Inc. (REPL)
  • Annexon, Inc. (ANNX)
  • REGENXBIO Inc. (RGNX)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Invivyd, Inc. (IVVD)
CTMX earnings history · CTMX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.